Hypersensitivity to antineoplastic agents: Mechanisms and treatment with rapid desensitization

Cancer Immunology, Immunotherapy

Volumn 61, Issue 9, 2012, Pages 1575-1584

  Castells, Mariana ^a   Del Carmen Sancho Serra, Maria ^a   Simarro, Maria ^b,c  

^a Division of Rheumatology Immunology and Allergy   (United States)

^b HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^c UNIVERSITY OF VALLADOLID   (Spain)

Author keywords

AllergoOncology Symposium in Writing; Chemotherapy drugs; Desensitization; Hypersensitivity reactions; Monoclonals

Indexed keywords

ABCIXIMAB; ANTIHISTAMINIC AGENT; BASILIXIMAB; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBOPLATIN; CETUXIMAB; CISPLATIN; CREMOPHOR; CYCLOSPORIN; DIPHENHYDRAMINE; DOCETAXEL; GLUCOCORTICOID; HISTAMINE; HYDROXYZINE; INFLIXIMAB; LEUKOTRIENE; METHYLPREDNISOLONE SODIUM SUCCINATE; MONOCLONAL ANTIBODY; NATALIZUMAB; OMALIZUMAB; OXALIPLATIN; PACLITAXEL; PLATINUM DERIVATIVE; PROSTAGLANDIN; RANITIDINE; RITUXIMAB; TAXANE DERIVATIVE; TRASTUZUMAB; UNINDEXED DRUG; VITAMIN K GROUP;

ABDOMINAL PAIN; ANGIONEUROTIC EDEMA; BACKACHE; BREAST CANCER; CARDIOVASCULAR SYMPTOM; CHILL; COLORECTAL CANCER; CONFERENCE PAPER; DESENSITIZATION; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG SAFETY; DYSPNEA; ERYTHEMA; FLUSHING; GASTROINTESTINAL SYMPTOM; HEART ARREST; HUMAN; HYPERTENSION; HYPOTENSION; LUNG NON SMALL CELL CANCER; MUSCLE DISEASE; NAUSEA; NECK PAIN; NEUROLOGIC DISEASE; NONHUMAN; OVARY CANCER; PARESTHESIA; PRESYNCOPE; PRIORITY JOURNAL; PRURITUS; RASH; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SKIN DISEASE; SOLID TUMOR; SYNCOPE; TACHYCARDIA; THORAX PAIN; THROAT TIGHTNESS; URTICARIA; VISUAL DISORDER; VOMITING; WEAKNESS; WHEEZING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DESENSITIZATION, IMMUNOLOGIC; DRUG HYPERSENSITIVITY; HUMANS;

EID: 84866533805     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1273-x     Document Type: Conference Paper

References (43)

1. Schwartz LB, Metcalfe DD, Miller JS, Earl H, Sullivan T (1987) Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med 316:1622-1626. doi:10.1056/NEJM198706253162603 (Pubitemid 17082588)
2. Vadas P, Gold M, Perelman B et al (2008) Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. N Engl J Med 358:28-35. doi:10.1056/NEJMoa070030
3. Castells M (2006) Desensitization for drug allergy. Curr Opin Allergy Clin Immunol 6:476-481. doi:10.1097/ACI.0b013e32 80108716 (Pubitemid 44714163)
4. Castells MC, Tennant NM, Sloane DE et al (2008) Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 122: 574-580. doi:10.1016/j.jaci.2008.02.044
5. Lee CW, Matulonis UA, Castells MC (2005) Rapid inpatient/ outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol 99:393-399. doi:10.1016/j.ygyno. 2005.06.028 (Pubitemid 41502850)
6. Lee CW, Matulonis UA, Castells MC (2004) Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. Gynecol Oncol 95:370-376. doi: 10.1016/j.ygyno.2004.08.002 (Pubitemid 39445874)
7. Wu LC (2011) Immunoglobulin E receptor signaling and asthma. J Biol Chem 286:32891-32897. doi:10.1074/jbc.R110.205104
8. Kepley CL (2005) Antigen-induced reduction in mast cell and basophil functional responses due to reduced Syk protein levels. Int Arch Allergy Immunol 138:29-39. doi:10.1159/000087355 (Pubitemid 41291563)
9. Shalit M, Levi-Schaffer F (1995) Challenge of mast cells with increasing amounts of antigen induces desensitization. Clin Exp Allergy 25:896-902
10. Sancho-Serra Mdel C, Simarro M, Castells M (2011) Rapid IgE desensitization is antigen specific and impairs early and late mast cell responses targeting FcepsilonRI internalization. Eur J Immunol 41:1004-1013. doi:10.1002/eji.201040810
11. Morales AR, Shah N, Castells M (2005) Antigen-IgE desensitization in signal transducer and activator of transcription 6-deficient mast cells by suboptimal doses of antigen. Ann Allergy Asthma Immunol 94:575-580. doi:10.1016/S1081-1206(10) 61136-2 (Pubitemid 40712782)
12. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD et al (1994) European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 12:2654-2666 (Pubitemid 24379653)
13. Kwon JS, Elit L, Finn M, Hirte H, Mazurka J, Moens F, Trim K (2002) A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel. Gynecol Oncol 84:420-425. doi:10.1006/gyno.2001.6546 (Pubitemid 34211869)
14. Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J (2000) Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J Clin Oncol 18:102-105 (Pubitemid 30036342)
15. Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E (1987) Phase I clinical and pharmacokinetic study of taxol. Cancer Res 47:2486-2493 (Pubitemid 17099218)
16. Schrijvers D, Wanders J, Dirix L, Prove A, Vonck I, van Oosterom A, Kaye S (1993) Coping with toxicities of docetaxel (Taxotere). Ann Oncol 4:610-611
17. Weiss RB, Donehower RC, Wiernik PH et al (1990) Hypersensitivity reactions from taxol. J Clin Oncol 8:1263-1268 (Pubitemid 20195638)
18. Price KS, Castells MC (2002) Taxol reactions. Allergy Asthma Proc 23:205-208
19. Decorti G, Bartoli Klugmann F, Candussio L, Baldini L (1996) Effect of paclitaxel and Cremophor EL on mast cell histamine secretion and their interaction with adriamycin. Anticancer Res 16:317-320 (Pubitemid 26128485)
20. Eschalier A, Lavarenne J, Burtin C, Renoux M, Chapuy E, Rodriguez M (1988) Study of histamine release induced by acute administration of antitumor agents in dogs. Cancer Chemother Pharmacol 21:246-250
21. Essayan DM, Kagey-Sobotka A, Colarusso PJ, Lichtenstein LM, Ozols RF, King ED (1996) Successful parenteral desensitization to paclitaxel. J Allergy Clin Immunol 97:42-46 (Pubitemid 26045967)
22. Szebeni J, Muggia FM, Alving CR (1998) Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst 90:300-306 (Pubitemid 28182386)
23. Weiszhar Z, Czucz J, Revesz C, Rosivall L, Szebeni J, Rozsnyay Z (2012) Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20. Eur J Pharm Sci 45:492-498. doi:10.1016/j.ejps.2011.09.016
24. Feldweg AM, Lee CW, Matulonis UA, Castells M (2005) Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. Gynecol Oncol 96:824-829. doi:10.1016/j.ygyno.2004. 11.043 (Pubitemid 40255508)
25. Aabo K, Adams M, Adnitt P et al (1998) Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer 78:1479-1487 (Pubitemid 28517545)
26. Gadducci A, Tana R, Teti G, Zanca G, Fanucchi A, Genazzani AR (2008) Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer. Int J Gynecol Cancer 18:615-620 (Pubitemid 352020152)
27. Gomez R, Harter P, Luck HJ, Traut A, Kommoss S, Kandel M, du Bois A (2009) Carboplatin hypersensitivity: does introduction of skin test and desensitization reliably predict and avoid the problem? A prospective single-center study. Int J Gynecol Cancer 19:1284-1287. doi:10.1111/IGC. 0b013e3181a418ff
28. Makrilia N, Syrigou E, Kaklamanos I, Manolopoulos L, Saif MW (2010) Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs. doi: 10.1155/2010/207084
29. Markman M, Kennedy A, Webster K, Elson P, Peterson G, Kulp B, Belinson J (1999) Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 17:1141
30. Maindrault-Goebel F, Andre T, Tournigand C, Louvet C, Perez-Staub N, Zeghib N, De Gramont A (2005) Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients. Eur J Cancer 41:2262-2267. doi:10.1016/j.ejca.2005.06.021 (Pubitemid 41415602)
31. Polyzos A, Tsavaris N, Gogas H et al (2009) Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience. Oncology 76:36-41. doi:10.1159/000178163
32. Sakaeda T, Kadoyama K, Yabuuchi H, Niijima S, Seki K, Shiraishi Y, Okuno Y (2011) Platinum agent-induced hypersensitivity reactions: data mining of the public version of the FDA adverse event reporting system, AERS. Int J Med Sci 8:332-338
33. Lee C, Gianos M, Klaustermeyer WB (2009) Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents. Ann Allergy Asthma Immunol 102: 179-187; quiz 87-89, 222. doi:10.1016/S1081-1206(10) 60078-6
34. Schwartz JR, Bandera C, Bradley A, Brard L, Legare R, Granai CO, Dizon DS (2007) Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants' Hospital. Gynecol Oncol 105:81-83. doi:10.1016/j.ygyno.2006.10.047 (Pubitemid 46441444)
35. Hesterberg PE, Banerji A, Oren E, Penson RT, Krasner CN, Seiden MV, Wong JT (2009) Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management. J Allergy Clin Immunol 123(1262-7):e1. doi: 10.1016/j.jaci.2009.02.042
36. Polyzos A, Tsavaris N, Kosmas C et al (2001) Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncology 61:129-133 (Pubitemid 32786206)
37. Dizon DS, Sabbatini PJ, Aghajanian C, Hensley ML, Spriggs DR (2002) Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynecol Oncol 84:378-382. doi: 10.1006/gyno.2001.6519 (Pubitemid 34211861)
38. Chung CH, O'Neil BH (2009) Infusion reactions to monoclonal antibodies for solid tumors: immunologic mechanisms and risk factors. Oncology (Williston Park) 23:14-17
39. Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ (2010) The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 9:325-338. doi:10.1038/nrd3003
40. Brennan PJ, Rodriguez Bouza T, Hsu FI, Sloane DE, Castells MC (2009) Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol 124:1259-1266. doi:10.1016/j.jaci.2009.09.009
41. Brown SG (2004) Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol 114:371-376. doi:10.1016/ j.jaci.2004.04.029 (Pubitemid 39119039)
42. Legere HJ 3rd, Palis RI, Rodriguez Bouza T, Uluer AZ, Castells MC (2009) A safe protocol for rapid desensitization in patients with cystic fibrosis and antibiotic hypersensitivity. J Cyst Fibros 8:418-424. doi:10.1016/j.jcf.2009.08. 002
43. Breslow RG, Caiado J, Castells MC (2009) Acetylsalicylic acid and montelukast block mast cell mediator-related symptoms during rapid desensitization. Ann Allergy Asthma Immunol 102:155-160. doi:10.1016/S1081- 1206(10)60247-5